Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CREBBP | Q92793 | 1/20 | 0.59 |
| ▸ | GAA | P10253 | 1/20 | 0.50 |
| ▸ | MAPT | P10636 | 1/20 | 0.50 |
| ▸ | PRKCD | Q05655 | 6/20 | 0.44 |
| ▸ | PRKCG | P05129 | 1/20 | 0.44 |
| ▸ | PRKCA | P17252 | 1/20 | 0.44 |
| ▸ | PNMT | P11086 | 4/20 | 0.41 |
| ▸ | MTNR1A | P48039 | 3/20 | 0.41 |
| ▸ | TRPM5 | Q9NZQ8 | 1/20 | 0.40 |
| ▸ | AR | P10275 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2450511 | 1.00 | CREBBP (0.59) | CREBBPGAAMAPTPRKCDPRKCG | |
| SCHEMBL29427458 | 1.00 | CREBBP (0.59) | CREBBPGAAMAPTPRKCDPRKCG | |
| SCHEMBL30681442 | 1.00 | CREBBP (0.59) | CREBBPGAAMAPTPRKCDPRKCG | |
| SCHEMBL30288510 | 1.00 | CREBBP (0.59) | CREBBPGAAMAPTPRKCDPRKCG | |
| SCHEMBL1193549 | 1.00 | CREBBP (0.59) | CREBBPGAAMAPTPRKCDPRKCG | |
| SCHEMBL16671960 | 0.85 | GAA (0.47) | CREBBPGAAMAPTPNMTMTNR1A | |
| SCHEMBL11319601 | 0.85 | GAA (0.47) | CREBBPGAAMAPTPNMTMTNR1A | |
| SCHEMBL14881136 | 0.82 | PNMT (0.47) | CREBBPGAAMAPTPNMTMTNR1A | |
| SCHEMBL11426860 | 0.82 | GAA (0.47) | CREBBPGAAMAPTPNMTMTNR1A | |
| SCHEMBL3441906 | 0.81 | MTNR1A (0.56) | CREBBPGAAMAPTPRKCDPRKCG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 203 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-117586170-B | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-04-09 | — | — | CN | claimed |
| CN-117586170-A | Indolinyl acyl derivative and synthetic method of isoquinoline formyl derivative | 江苏集萃分子工程研究院有限公司 | 2024-02-23 | — | — | CN | claimed |
| CN-110279121-A | A kind of Oligopeptide Compositions and preparation method thereof | 海盐县凌特生物科技有限公司 | 2019-09-27 | — | — | CN | claimed |
| EP-2470508-A1 | CANNABINOID RECEPTOR MODULATORS | Arena Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | claimed |
| WO-2011025541-A1 | CANNABINOID RECEPTOR MODULATORS | ARENA PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | claimed |
| CN-101657457-A | Be used to prepare 1,3, the method for 2-oxa-boron acridine compound | ZACH SYSTEM FR | 2010-02-24 | — | — | CN | claimed |
| US-7586015-B2 | Process for the preparation of 1,3,2-oxazaborolidine compounds | ZACH SYSTEM (FR) | 2009-09-08 | — | — | US | claimed |
| US-20080139851-A1 | R2, R3, R4 and R5 are especially a hydrogen atom or an alkyl,wherein the following are reacted in two steps:a) a boric precursor compound with an acetal compound to give a boronate compound; and) the boronate compound with an amino alcohol compound | PPG-SIPSY (FR) | 2008-06-12 | — | — | US | claimed |
| US-12516053-B2 | Bcl-2 inhibitors | BEONE MEDICINES I GMBH (CH) | 2026-01-06 | — | — | US | disclosed |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | MONTE ROSA THERAPEUTICS AG (CH) | 2025-05-29 | — | — | US | disclosed |
| US-12312349-B2 | Apoptosis-inducing agents | FOCHON PHARMACEUTICALS, LTD. (CN) | 2025-05-27 | — | — | US | disclosed |
| EP-4540240-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | Monte Rosa Therapeutics AG (CH) | 2025-04-23 | — | — | EP | disclosed |
| WO-2024201248-A1 | COMPOUNDS AND METHODS FOR DEGRADING GSPT1 | PIN THERAPEUTICS, INC. (KR) | 2024-10-03 | — | — | WO | disclosed |
| WO-2024120471-A1 | COMPOUNDS TARGETING MUTANT OF P53 | JACOBIO PHARMACEUTICALS CO., LTD. (CN) | 2024-06-13 | — | — | WO | disclosed |
| EP-0642508-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1995-03-15 | — | — | EP | disclosed |
| CN-1094038-A | The amino pyrazoles that replaces | PFIZER (US) | 1994-10-26 | — | — | CN | disclosed |
| WO-1994013644-A1 | AMINO-SUBSTITUTED PYRAZOLES HAVING CRF ANTAGONISTIC ACTIVITY | PFIZER INC. (US) | 1994-06-23 | — | — | WO | disclosed |
| WO-1993008188-A1 | TRICYCLIC QUINOXALINEDIONES AS GLUTAMATE RECEPTOR ANTAGONISTS | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 1993-04-29 | — | — | WO | disclosed |
| US-4260628-A | 2-Guanidinomethyl-indolines | MERCK PATENT GESELLSCHAFT MIT BESCHRANKTER HAFTUNG (DE) | 1981-04-07 | — | — | US | disclosed |
| US-4153699-A | ANALGESIC, ANTIPYRETIC, ANTIINFLAMMATORY | RHONE-POULENC INDUSTRIES (FR) | 1979-05-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080139851-A1 | R2, R3, R4 and R5 are especially a hydrogen atom or an alkyl,wherein the following are reacted in two steps:a) a boric precursor compound with an acetal compound to give a boronate compound; and) the boronate compound with an amino alcohol compound | ADH1A, ADH1C, ADH5 | CREBBP 1036/4885GAA 4784/4885MAPT 3759/4885 |
| US-12312349-B2 | Apoptosis-inducing agents | BCL2, BAX, BAD | CREBBP 116/4885GAA 2247/4885MAPT 3573/4885 |
| US-20250171420-A1 | MOLECULAR GLUE DEGRADERS AND METHODS OF USING THE SAME | PSMA1, CSNK1G1, CSNK1A1 | CREBBP 2136/4885GAA 234/4885MAPT 614/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.